Lionheart Health, Inc., a leader in bioelectric regeneration and longevity biotechnology, announced the filing of a non-provisional U.S. patent for its platform technology: Bioelectric-Enhanced Klotho Nanoflowers for Aging Reversal and Healthspan Extension. The patent protects a therapeutic system that integrates nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging.
The platform centers on engineered 'nanoflowers'—flower-shaped hybrid nanoparticles capable of upregulating Klotho, a longevity-associated protein, restoring mitochondrial function by enhancing ATP production and reducing oxidative stress, delivering targeted bioactive agents including peptides, plasmids, mRNA, and CRISPRa activators, acting as nanozyme catalysts that reduce ROS, and enhancing regenerative signaling when activated by precise bioelectric patterns. The nanoflowers are engineered to respond to Lionheart's proprietary bioelectric stimulation sequences, which increase cellular uptake, activate intracellular pathways, and amplify biological performance.
Howard J. Leonhardt, Founder and CEO of Lionheart Health, stated, 'This invention represents the convergence of three of the most powerful emerging technologies in biotechnology—bioelectric signaling, nanomedicine, and Klotho modulation. Our goal is to create a system that reverses biological age at the cellular level and enhances healthspan safely, non-invasively, and affordably.'
The nanoflowers require bioelectric activation for optimal performance, and the bioelectric component is designed to operate in the presence of the nanoflowers. Bioelectric stimulation opens ion channels, improves endocytosis, directs nanoflowers toward mitochondria, and triggers therapeutic payload release. Klotho expression increases due to both nanoflower-delivered genetic or peptide payloads and bioelectric activation of promoter and epigenetic pathways, demonstrating a combined therapeutic benefit.
The technology is designed for system-wide healthspan improvement, including mitochondrial biogenesis via activation of PGC-1α, NRF1/2, and TFAM, reduction of cellular senescence through lower oxidative stress, and stabilization of biological age via combined mitochondrial repair and Klotho enhancement. Klotho is widely recognized as a promising longevity molecule; decreased levels are associated with accelerated aging, cognitive decline, inflammation, vascular calcification, kidney dysfunction, and frailty.
Dr. Leslie Miller, Chief Medical Officer and former President of the International Society for Heart and Lung Transplantation, said, 'Bioelectric-enhanced Klotho nanoflowers give us a programmable, multi-modal tool to address the root causes of aging—declining energy production, rising inflammation, and loss of regenerative capacity. This filing marks a major milestone in longevity therapeutics.'
The patent filing adds to Lionheart Health's growing intellectual property portfolio spanning bioelectric-controlled protein expression, stem-cell mobilization, mitochondrial restoration, and Klotho-based gene therapy. Lionheart Health is preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics across the U.S. and internationally, and plans to integrate the technology into its XPRIZE Healthspan competition program.
